

What is Claimed is:

- ~~1. A method for inhibiting apoptosis of a cell comprising treating the cell with an effective amount of a Receptor Internalization and Degradation (RID) complex.~~
- ~~2. The method of claim 1 wherein the treating step comprises administering to the cell a polynucleotide encoding the RID complex and wherein the RID complex is expressed in the cell.~~
- ~~Sub B² 3. The method of claim 2 wherein the polynucleotide comprises a recombinant adenovirus vector.~~
- ~~4. The method of claim 3 wherein the recombinant adenovirus vector is 231-10.~~
- ~~5. The method of claim 3 wherein the cell expresses Fas, TNFR-1, DR3, TRAIL-R1, or TRAIL-R2.~~
- ~~Sub B³ 6. The method of claim 5 wherein the cell is a leukocyte.~~
- ~~7. The method of claim 5 wherein the cell comprises a transplant tissue.~~
- ~~8. The method of claim 1 wherein the treating step comprises administering the RID complex to the cell.~~
- ~~9. The method of claim 8 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the cell.~~
- ~~10. A method for decreasing apoptosis of target cells in a patient comprising treating the patient with an effective amount of a Receptor Internalization and Degradation (RID) complex.~~
- ~~11. The method of claim 10 wherein the treating step comprises administering to the patient a polynucleotide encoding the RID complex and wherein the polynucleotide is internalized in the target cells and the RID complex is expressed.~~
- ~~Sub B⁵ 12. The method of claim 11 wherein the polynucleotide comprises a recombinant adenovirus vector.~~
- ~~13. The method of claim 12 wherein the recombinant adenovirus vector is 231-10.~~
- ~~14. The method of claim 10 wherein the patient suffers from a degenerative disease or an immunodeficiency disease.~~
- ~~15. The method of claim 10 wherein the treating step comprises administering the RID complex to the patient.~~
- ~~16. The method of claim 15 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the cells.~~
- ~~17. A method for decreasing leukocyte apoptosis in a patient comprising:~~
 - ~~(1) withdrawing leukocytes from the patient,~~
 - ~~(2) treating the leukocytes with an effective amount of a RID complex, and~~
 - ~~(3) administering the treated leukocytes to the patient.~~

18. The method of claim 17 wherein the treating step comprises administering to the leukocytes a polynucleotide encoding the RID complex wherein the RID complex is expressed in the leukocytes.

Sub B7 19. The method of claim 18 wherein the polynucleotide comprises a recombinant adenovirus vector.

20. The method of claim 19 wherein the recombinant adenovirus vector is 231-10.

21. The method of claim 17 wherein the treating step comprises administering the RID complex to the leukocytes.

22. The method of claim 21 wherein the RID complex is administered with a carrier which facilitates delivery of the RID complex into the leukocytes.

23. A composition comprising a Receptor Internalization and Degradation (RID) complex and a carrier suitable for facilitating delivery of the RID complex into a cell.

24. A recombinant adenovirus comprising a polynucleotide encoding a Receptor Internalization and Degradation (RID) complex operably linked to a promoter, wherein the adenovirus is replication defective and wherein the polynucleotide is expressed upon infection of a eukaryotic cell with the adenovirus.

25. The recombinant adenovirus vector of claim 24 consisting of 231-10.

Sub
B7
05

Walt
05

BEST AVAILABLE COPY